FARROWSURE PLUS B Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

farrowsure plus b

pfizer croatia d.o.o., zagreb, hrvatska - parvovirus svinja, soj nadl-7; erysipelothrix rhusiopathiae, soj cn 3342; leptospira bratislava, soj jez; l. canicola, soj c-51; l.grippotyphosa, soj mal 1540; l.hatdjo, soj who; l. icterohaemorrhagiae, soj nadl (11403) i l. pomona, soj t262 - injekcijska emulzija - svinja

Vpriv Europska Unija - hrvatski - EMA (European Medicines Agency)

vpriv

takeda pharmaceuticals international ag ireland branch - velagluceraza alfa - gaucherova bolest - drugi gastrointestinalni trakt i metabolizam, lijekovi, - vpriv je indiciran za dugoročnu zamjensku enzimsku terapiju (ert) u bolesnika s tipom 1 gaucherove bolesti.

Cyltezo Europska Unija - hrvatski - EMA (European Medicines Agency)

cyltezo

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - imunosupresivi - molimo pogledajte odjeljak 4. 1 sažetak značajki proizvoda u dokumentu o informacijama o proizvodu.

TERMODILUCIJSKI KATETERI Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

termodilucijski kateteri

sonimed d.o.o., zagreb - kateter putem kojeg se mjeri vrijednost rada srca u smislu snage izbačaja i volumena izbačene krvi

Vidaza Europska Unija - hrvatski - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.